Shares of Viveve Medical Inc (NASDAQ:VIVE) gapped down prior to trading on Wednesday . The stock had previously closed at $0.17, but opened at $0.16. Viveve Medical shares last traded at $0.17, with a volume of 694,827 shares changing hands.
VIVE has been the topic of several recent analyst reports. LADENBURG THALM/SH SH lowered shares of Viveve Medical from a “buy” rating to a “neutral” rating in a report on Wednesday. Raymond James reissued a “hold” rating and issued a $32.00 target price on shares of State National Companies in a report on Tuesday. Stifel Nicolaus downgraded shares of Viveve Medical from a “buy” rating to a “hold” rating and reduced their price target for the company from $3.00 to $1.00 in a research note on Monday. Maxim Group downgraded shares of Viveve Medical from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Mizuho reduced their price target on shares of Marinus Pharmaceuticals from $5.00 to $1.70 and set a “neutral” rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $2.24.
The company’s 50 day moving average is $0.41. The company has a debt-to-equity ratio of 6.21, a current ratio of 3.95 and a quick ratio of 3.43. The company has a market cap of $18.96 million, a P/E ratio of -0.11 and a beta of -0.11.
Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. Viveve Medical had a negative net margin of 265.51% and a negative return on equity of 2,979.48%. The company had revenue of $3.01 million for the quarter, compared to the consensus estimate of $2.98 million. As a group, equities analysts expect that Viveve Medical Inc will post -0.73 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Accredited Investors Inc. acquired a new stake in shares of Viveve Medical in the 1st quarter valued at approximately $31,000. Bank of New York Mellon Corp boosted its stake in shares of Viveve Medical by 266.6% in the 4th quarter. Bank of New York Mellon Corp now owns 45,223 shares of the company’s stock valued at $47,000 after purchasing an additional 32,888 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Viveve Medical by 13.6% in the 4th quarter. Geode Capital Management LLC now owns 216,566 shares of the company’s stock valued at $227,000 after purchasing an additional 25,975 shares in the last quarter. Meitav Dash Investments Ltd. boosted its stake in shares of Viveve Medical by 30.1% in the 1st quarter. Meitav Dash Investments Ltd. now owns 988,573 shares of the company’s stock valued at $955,000 after purchasing an additional 228,517 shares in the last quarter. Finally, Pennsylvania Trust Co boosted its stake in shares of Viveve Medical by 212.3% in the 1st quarter. Pennsylvania Trust Co now owns 42,154 shares of the company’s stock valued at $7,681,000 after purchasing an additional 28,654 shares in the last quarter. Institutional investors own 59.72% of the company’s stock.
About Viveve Medical (NASDAQ:VIVE)
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.